TrialDiabetes care2013

Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.

Ele Ferrannini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.